Literature DB >> 1671650

Surrogate end points in clinical trials.

S S Ellenberg.   

Abstract

Mesh:

Substances:

Year:  1991        PMID: 1671650      PMCID: PMC1668902          DOI: 10.1136/bmj.302.6768.63

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Surrogate endpoints in clinical trials: ophthalmologic disorders.

Authors:  A Hillis; D Seigel
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

2.  Surrogate endpoints in clinical trials: cardiovascular diseases.

Authors:  J Wittes; E Lakatos; J Probstfield
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

3.  Surrogate endpoints in clinical trials: cancer.

Authors:  S Ellenberg; J M Hamilton
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

4.  On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection.

Authors:  S G Machado; M H Gail; S S Ellenberg
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

5.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

6.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

  6 in total
  4 in total

1.  Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS?

Authors:  D R Bainbridge; M W Lowdell; I M Hannet; K W Strauss; A Karpas
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-07-29       Impact factor: 6.237

2.  Surrogate endpoints.

Authors:  S S Ellenberg
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

3.  Retention loss of resin based fissure sealants - a valid predictor for clinical outcome?

Authors:  Steffen Mickenautsch; Veerasamy Yengopal
Journal:  Open Dent J       Date:  2013-08-23

4.  Clinically Relevant Immune-Cellular Metrics of Inflammation in Meibomian Gland Dysfunction.

Authors:  Yureeda Qazi; Ahmad Kheirkhah; Caroline Blackie; Monique Trinidad; Candice Williams; Andrea Cruzat; Donald R Korb; Pedram Hamrah
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-12-03       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.